Romero-Riquelme, Mónica-Alejandra; Aspas-Requena, Gaspar; Lloret-Madrid, Pilar; Gil, Cristina; Aguiar, Eliana; Tormo, Mar; del-Bernal-del-Castillo, Teresa; Rodríguez-Arboli, Eduardo; Serrano, Josefina; Sánchez-García, Joaquin; Rodríguez-Medina, Carlos; Mariz, José-Mario; Ayala, Rosa; Martínez-López, Joaquin; Amigo, María-Luz; Vives, Susana; Algarra-Algarra, Lorenzo; García-Boyero, Raimundo; Brioso, Joana; Castano, Tamara; Bergua-Burgues, Juan-Miguel; Salamero, Olga; Bass-Maturana, María-Francisca; Colorado, Mercedes; García-Fortes, María; Sayas-Lloris, María-José; Vicente, Belén-Vidriales; Chillon, Carmen; Pérez-Santaolalla, Esther; Madrigal, María-Dolores; Labrador-Gómez, Jorge; García-Pérez, María-José; Casado-Calderon, Soledad; Pérez-Encinas, Manuel; Balerdi-Malcorra, Amaia; Rodríguez, María-Sole; Gómez-García, Lara-María; Herrera-Puente, Pilar; Arce-Fernández, Olga; Barrios-García, Manuel; Noriega, Victor; Fernández, Rosa; Mateos, Mamen; Lacalzada, Carolina; Almela-Gallego, Agata; García-Garay, María-Carmen; Couto, Carmen; Pérez-Simon, José-Antonio; Barragan-González, Eva; Montesinos, Pau
(WILEY, 2026-11)
Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real-world ...